• Baked In
  • Posts
  • 👀 WAIT AND SEE 👀

👀 WAIT AND SEE 👀

Have we paused the Rally?

Author

William McNarland
April 12, 2024

GM Everyone,

Yesterday, our friend of the program, Representative Nancy Mace, posed the only question that truly matters: "Do you think rescheduling happens this year?" To our surprise, the DEA responded, "There's no reason for DEA to delay. They have to take into account all of the regulations at play." While this answer was music to some ears, it gave us a moment of pause. Indeed, there is absolutely no reason to delay, but as we know, the rescheduling review of a drug can take well over a year, and we are only a little over the 6-month mark in the process. While these statements caused fireworks, we remain cautious and will be watching the process very closely.

Today’s letter can be read in 5 minutes and 42seconds. 

  • The FDA/DEA continue to dance so when can we expect an answer

  • Psychedelics coming to an insurer near you?!!?!?

  • The BTC halving is a week away. Are you prepared?

  • The boys were live from the steps of the Capitol with Don Murphy in our first video in the series from Washington

Capital Markets this Morning:

The futures are down a little bit, especially tech stocks. Here is what is in focus globally for stocks:

  • U.S. earnings season kicks off with big banks, tech firms poised to lead S&P 500 profit growth.

  • China's trade slump in March surprises markets, impacting global economic sentiment.

  • Rising Middle East tensions add safety bids to bonds; gold hits a new record high.

  • U.S. producer price softening and cautious Fed commentary stabilize rate expectations.

  • Dollar strengthens as ECB hints at June rate cut, overshadowing Fed's hesitancy.

Cannabis Regulation: FDA Continues to Push the DEA for Rescheduling

The TDR Takeaway: FDA Commissioner Robert Califf, speaking at a House Oversight and Accountability Committee hearing, argued forcefully that there is no valid reason for the DEA to delay shifting cannabis from Schedule I to Schedule III under the Controlled Substances Act. Will the DEA listen? For more details, visit the TDR website. 

Psychedelics: More Employers willing to pay for Psychedelic Therapy

The TDR Takeaway: Companies like Plexis Healthcare are pioneering the integration of Psychedelic-Assisted Therapy, enhancing traditional mental health support. This a real big win for Psychedelic companies whose revenues with be strengthen as more insurance companies pay for treatment. For more information, read about it on the TDR website.

Crypto: What Investors Need to Know About the Bitcoin Halving

The TDR Takeaway: The upcoming Bitcoin halving will slash the mining reward from 6.25 to 3.125 Bitcoins, potentially heightening market interest. Strategic shifts by miners and increased institutional investments suggest a complex reaction to the Bitcoin halving.Despite uncertainties, the reduction in Bitcoin supply paired with strong  demand could signal significant upward price movements. For more information, read about it on the TDR website.

AI News: Features and Flaws of the New Ai Pin

The TDR Takeaway! This week’s  introduction of the Humane Ai Pin, priced at $700, has garnered significant interest within the tech community. Supported by Sam Altman and companies like Microsoft, the Ai Pin represents a new development in artificial intelligence technology. Despite its groundbreaking design, the Ai Pin exhibits several flaws that could hinder its widespread acceptance. Read all about it on the TDR Website!

In yesterday’s episode of TDR's Trade To Black, we premiere our interview with Don Murphy on Capitol Hill's footsteps and discuss our takeaways from the trip. Who we talked to? What did we do? Find out.